Please try another search
Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.
Name | Age | Since | Title |
---|---|---|---|
Lian Zhong | 64 | - | Independent Director |
Yu Pinxiang | 51 | 2020 | Executive VP & Director |
Shaobin Zeng | 47 | 2020 | Non-Independent Director |
Di Yang | 39 | 2021 | VP, Secretary & Director |
Shaogui Zeng | 56 | 2021 | Chairman |
Lu Yang | 42 | 2021 | Member of Non-Employee Supervisory Board |
Yao Li | 47 | 2021 | Independent Director |
Lin Liang | 47 | - | Supervisor |
Shaoqiang Zeng | 53 | 2021 | Vice Chairman |
Yangming Tang | 46 | 2021 | VP & Director |
Wenyan Hu | 54 | 2021 | Independent Director |
Qingyang Li | 48 | 2021 | Chairman of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review